e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Asthma management and response
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Quantitative IgE levels in asthma and implications for treatment with omalizumab. Are the cutoffs to narrow?
M. L. Zaremba, K. Elliott, A. Redford, N. Shah, S. Ali, S. Reddy (Port Huron, United States Of America)
Source:
Annual Congress 2011 - Asthma management and response
Session:
Asthma management and response
Session type:
Thematic Poster Session
Number:
3962
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. L. Zaremba, K. Elliott, A. Redford, N. Shah, S. Ali, S. Reddy (Port Huron, United States Of America). Quantitative IgE levels in asthma and implications for treatment with omalizumab. Are the cutoffs to narrow?. Eur Respir J 2011; 38: Suppl. 55, 3962
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Treatment of asthma above and beyond anti IgE: an update for the clinician The use of biologicals in asthma treatment
Source: International Congress 2018 – Difficult paediatric lung disease
Year: 2018
Free serum IgE suppression with omalizumab and clinical outcomes in asthma
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019
Correlation between specific serum IgE and exhaled NO levels at low and high inhaled corticosteroid use in allergic asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 276s
Year: 2005
Long-term efficacy of omalizumab (OMA) for patients with severe allergic asthma (SAA). Clinical assessment and relationship to serum IgE concentrations
Source: International Congress 2015 – The immunology of allergic airway disease
Year: 2015
Relationship between omalizumab efficacy and baseline allergen profile impacts patient-reported outcomes in allergic asthma
Source: International Congress 2018 – Tests and trends in asthma
Year: 2018
Correlation of changes of IgE with skin reactivity and clinical outcome during specific immunotherapy against home dust in asthmatic subjects
Source: Annual Congress 2012 - Phenotypes and mechanisms of treatment of asthma
Year: 2012
Clinical significance of serum MRGPRX2 as a new biomarker in allergic asthma
Source: International Congress 2019 – Research and innovation in airway diseases
Year: 2019
Returning asthma symptoms correlate with free IgE upon omalizumab cessation
Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Year: 2007
Possible impact of serum IgE variability on dose calculation of omalizumab (anti-IgE)
Source: Eur Respir J 2004; 24: Suppl. 48, 220s
Year: 2004
Monitoring free serum IgE in asthma patients treated with omalizumab
Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Year: 2010
Impact of omalizumab treatment persistence on asthma control
Source: Annual Congress 2012 - Aspects of clinical asthma
Year: 2012
Effect of urbanisation on the relationship between total serum IgE and asthma
Source: Eur Respir J 2013; 41: 1074-1081
Year: 2013
Relationship between pre-treatment specific IgE and the response to omalizumab therapy
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
Measuring airway hyperresponsiveness: does it add to routine measures of clinical efficacy in guiding asthma therapy?
Source: Eur Respir J 2006; 28: Suppl. 50, 319s
Year: 2006
Real life effectiveness of omalizumab in severe allergic asthma, does the IgE level matter? A Bradford experience
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
Optimal cut-off value and clinical usefulness of adherence starts with knowledge-12 (ASK-12) in asthmatic patients taking inhaled corticosteroid
Source: International Congress 2016 – Notable abstracts on clinical problems related to asthma
Year: 2016
Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy
Source: Eur Respir Rev 2007; 16: 73-77
Year: 2007
Monitoring free serum IgE in severe asthma patients treated with omalizumab
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011
How specific and sensitive are commercial specific IgE assays in the diagnosis of occupational asthma and allergy?
Source: Annual Congress 2009 - Occupational asthma in the clinic
Year: 2009
Long-term bortezomib treatment decreases allergen-specific IgE but fails to amend chronic asthma in mice
Source: Annual Congress 2012 - Asthma: mechanisms of airway inflammation
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept